Clinical proteomics: A need to define the field and to begin to set adequate standards.
The aim of this manuscript is to initiate a constructive discussion about the definition of clinical proteomics, study requirements, pitfalls and (potential) use. Furthermore, we hope to stimulate proposals for the optimal use of future opportunities and seek unification of the approaches in clinical proteomic studies. We have outlined our collective views about the basic principles that should be considered in clinical proteomic studies, including sample selection, choice of technology and appropriate quality control, and the need for collaborative interdisciplinary efforts involving clinicians and scientists. Furthermore, we propose guidelines for the critical aspects that should be included in published reports. Our hope is that, as a result of stimulating discussion, a consensus will be reached amongst the scientific community leading to guidelines for the studies, similar to those already published for mass spectrometric sequencing data. We contend that clinical proteomics is not just a collection of studies dealing with analysis of clinical samples. Rather, the essence of clinical proteomics should be to address clinically relevant questions and to improve the state-of-the-art, both in diagnosis and in therapy of diseases.
Mosaiques Diagnostics, Hannover, Germany. mischak@mosaiques-diagnostics.com.
Harald
H
Mischak
Rolf
R
Apweiler
Rosamonde E
RE
Banks
Mark
M
Conaway
Joshua
J
Coon
Anna
A
Dominiczak
Jochen H H
JH
Ehrich
Danilo
D
Fliser
Mark
M
Girolami
Henning
H
Hermjakob
Denis
D
Hochstrasser
Joachim
J
Jankowski
Bruce A
BA
Julian
Walter
W
Kolch
Ziad A
ZA
Massy
Christian
C
Neusuess
Jan
J
Novak
Karlheinz
K
Peter
Kasper
K
Rossing
Joost
J
Schanstra
O John
OJ
Semmes
Dan
D
Theodorescu
Visith
V
Thongboonkerd
Eva M
EM
Weissinger
Jennifer E
JE
Van Eyk
Tadashi
T
Yamamoto